A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Inclusion Criteria: * At least 18 years of age at the time of screening * Documented diagnosis of HAE (Type I or II) * Experiencing ≥2 HAE attacks per year, with at least 1 attack in the past 6 months reported by the participant * Willing and able to read, understand, and sign an informed consent form * Females of childbearing potential must agree to be abstinent or else use acceptable forms of contraception throughout study * Males with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception throughout study Exclusion Criteria: * Exposure to an investigational drug or device within 90 days prior to study * History of exposure within the past 5 years to a monoclonal antibody or recombinant protein bearing an Fc domain * Concomitant diagnosis of another form of chronic angioedema * Use of long-term prophylaxis for HAE within 90 days prior to study * Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study; any use of C1-INH within 7 days prior to study * Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption within 90 days prior to study * Exposure to androgens within 90 days prior to study * Presence of an indwelling catheter * Diagnosis of HIV * Active liver disease or liver function test abnormalities * History of substance abuse or dependence * Pregnancy or breastfeeding * Any condition that, in the opinion of the Investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results